Ausgabe 1/2008
Inhalt (22 Artikel)
A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer
Sun Jin Sym, Heung Moon Chang, Hye Jin Kang, Sung Sook Lee, Min-Hee Ryu, Jae-Lyun Lee, Tae-Won Kim, Jeong Hwan Yook, Sung Tae Oh, Byung Sik Kim, Yoon-Koo Kang
Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study
Peter Mu-Hsin Chang, Po-Min Chen, Pen-Yuan Chu, Ling-Wei Wang, Shyh-Kuan Tai, Tung-Lung Tsai, Jui-Lin Huang, Yi-Fen Wang, Shyue-Yih Chang, Muh-Hwa Yang
Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model
Michael J. Kelner, Trevor C. McMorris, Rafael J. Rojas, Leita A. Estes, Pharnuk Suthipinijtham
Resveratrol analog trans 3,4,5,4′-tetramethoxystilbene (DMU-212) mediates anti-tumor effects via mechanism different from that of resveratrol
Zengshuan Ma, Ommoleila Molavi, Azita Haddadi, Raymond Lai, Robert A. Gossage, Afsaneh Lavasanifar
Inhibition of mitochondrial protein translation sensitizes melanoma cells to arsenic trioxide cytotoxicity via a reactive oxygen species dependent mechanism
Benjamin D. Bowling, Nicole Doudican, Prashiela Manga, Seth J. Orlow
In vitro and in vivo effects of the conformationally restricted polyamine analogue CGC-11047 on small cell and non-small cell lung cancer cells
Amy Hacker, Laurence J. Marton, Michelle Sobolewski, Robert A. Casero Jr.
Does saturable formation of gemcitabine triphosphate occur in patients?
Lai-San Tham, Ling-Zhi Wang, Ross A. Soo, How-Sung Lee, Soo-Chin Lee, Boon-Cher Goh, Nicholas H. G. Holford
A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies
Laura Q. M. Chow, Daniel L. Gustafson, Cindy L. O’Bryant, Lia Gore, Michele Basche, Scott N. Holden, Mark C. Morrow, Stacy Grolnic, Brian R. Creese, Kaye L. Roberts, Kat Davis, Russell Addison, S. Gail Eckhardt
Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting
Susumu Nakade, Tomoya Ohno, Junsaku Kitagawa, Yoshitaka Hashimoto, Masahiro Katayama, Hiroshi Awata, Yasuo Kodama, Yasuyuki Miyata
High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1
Hidekazu Kuramochi, Kazuhiko Hayashi, Kazumi Uchida, Go Nakajima, Takashi Hatori, Kathleen D. Danenberg, Peter V. Danenberg, Masakazu Yamamoto
Gastrointestinal dysmotility in 5-fluorouracil-induced intestinal mucositis outlasts inflammatory process resolution
Pedro M. G. Soares, José Maurício S. C. Mota, Antoniella S. Gomes, Ricardo B. Oliveira, Ana Maria S. Assreuy, Gerly Anne C. Brito, Armênio A. Santos, Ronaldo A. Ribeiro, Marcellus H. L. P. Souza
A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors
E. Claire Dees, Bert H. O’Neil, Celeste M. Lindley, Frances Collichio, Lisa A. Carey, Jason Collins, William J. Riordan, Anastasia Ivanova, Dixie Esseltine, Robert Z. Orlowski
A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer
Noelle K. LoConte, James P. Thomas, Dona Alberti, Jennifer Heideman, Kimberly Binger, Rebecca Marnocha, Kyle Utecht, Peter Geiger, Jens Eickhoff, George Wilding, Jill Kolesar
Antitumor activity of noscapine in human non-small cell lung cancer xenograft model
Tanise Jackson, Mahavir B. Chougule, Nkechi Ichite, Ram R. Patlolla, Mandip Singh
In vitro evaluation of dichloro-bis(pyrazole)palladium(II) and dichloro-bis(pyrazole)platinum(II) complexes as anticancer agents
Frankline K. Keter, Stonard Kanyanda, Sylvester S. L. Lyantagaye, James Darkwa, D. Jasper G. Rees, Mervin Meyer
Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR positive advanced colorectal cancer treated with gefitinib?
M. G. Zampino, E. Magni, L. Santoro, L. Zorzino, P. Dell’Orto, A. Sonzogni, N. Fazio, L. Monfardini, A. Chiappa, R. Biffi, F. de Braud
Gemcitabine at fixed dose-rate in patients with advanced soft tissue sarcomas: a mono-institutional phase II study
Virginia Ferraresi, Mariangela Ciccarese, Maria Cecilia Cercato, Carmen Nuzzo, Massimo Zeuli, Franco Di Filippo, Diana Giannarelli, Francesco Cognetti
Preclinical discovery of ixabepilone, a highly active antineoplastic agent
Francis Y. F. Lee, Robert Borzilleri, Craig R. Fairchild, Amrita Kamath, Richard Smykla, Robert Kramer, Gregory Vite
Comparison of the in vitro and in vivo effects of retinoids either alone or in combination with cisplatin and 5-fluorouracil on tumor development and metastasis of melanoma
Xin Liu, Sui Yung Chan, Paul Chi-Lui Ho
A phase I study of gemcitabine plus palliative radiation therapy for advanced lung cancer
Brian Choi, H. Ian Robins, Joan Schiller, Minesh Mehta
Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors
Wells A. Messersmith, Antonio Jimeno, David Ettinger, Dan Laheru, Julie Brahmer, Dina Lansey, Yasmin Khan, Ross C. Donehower, Yusri Elsayed, Peter Zannikos, Manuel Hidalgo
Response to taxanes in triple negative breast cancer
Nilufer Bulut, Sadettin Kilickap, Ebru Sari, Kadri Altundag